Stada Partners With Calliditas On Novel Budesonide Formulation

Deal Worth Over $100m Targets First European Approval For Orphan IgAN Treatment

Stada has struck a licensing and commercialization deal with Calliditas worth more than $100m to partner on a novel oral formulation of budesonide to treat Immunoglobulin A Nephropathy in Europe.

Stada logo magnifying glass
Stada has partnered with Calliditas on its innovative budesonide formulation • Source: Alamy

Stada has struck a licensing and commercialization deal with Sweden’s Calliditas worth at least €97.5m ($114.8m) covering a novel oral formulation of budesonide intended to treat rare chronic autoimmune kidney disease Immunoglobulin A Nephropathy in Europe.

Insisting that the partnership for the oral orphan-drug candidate “combines Calliditas’ drug-delivery expertise with Stada’s go-to-partner strategy and pan-European marketing...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business